Founded in 1992, Crimson is the only translation practice devoted exclusively to Class II and III devices and List A and B IVDs. Crimson is the only translation organization in the world certified to ISO 9001:2000, ISO 13485:2003 and registered to ISO 14971:2000. Crimson has received official Notified Body recognition for its innovative application of the SAE J2450 translation quality standard. The company's specialized approach to translation risk management is the basis of the industry’s only risk management patent (pending).

Crimson's specialized approach to medical technology translation has been featured in industry publications such as Medical Device & Diagnostics Industry, BI&T Journal (AAMI publication), Orthopedic Design & Technology, and Medical Products Outsourcing.

The firm's founder, Marc H. Miller, provides management guidance. Mr. Miller holds a degree in languages and literature from Harvard University and an MBA from the Scottish Business School in Stirling, Scotland. While working as a Senior Research Fellow with the international strategy consulting firm S.I.A.R., Mr. Miller authored strategic assessments for European and US medical technology firms.

Key process development guidance is provided by Kai Simonsen, Crimson’s VP of Production & Quality Systems. Co-author of the industry's first risk management patent, Mr. Simonsen has been responsible for the development and implementation of Crimson’s specialized production and quality systems since 2002. A native of Flensburg, Germany, he completed his undergraduate studies in English, Education, and Physics, and has held various positions in the translation and localization field since 1997.

In 2005, Crimson joined the growing TransPerfect family of companies. Clients benefit from Crimson's audited quality and risk management systems, combined with the extensive resources and localization talent of TransPerfect and its software localization unit, Translations.com.